Table 1.
Characteristics of prophylactic DLI recipients and donors
| Variable | Number | Percentage |
|---|---|---|
| Age of patient at transplantation (years) | ||
| Median (range) | 34 (18–57) | |
| < 40/ ≥ 40 | 20/11 | 64.5%/35.5% |
| Gender | ||
| Male/female | 18/13 | 58.1%/41.9% |
| WBC count at diagnosisa | ||
| < 30 × 109/L/ ≥ 30 × 109/L | 21/7 | 67.7%/22.6% |
| Diagnosis | ||
| AML | 21 | 67.7% |
| ALL/LBL | 5 | 15.6% |
| CML | 2 | 6.5% |
| NHL | 2 | 6.5% |
| PCL | 1 | 3.2% |
| Disease status at transplantation | ||
| Primary induction failure | 6 | 19.4% |
| Relapse untreated or refractory to reinduction CT | 4 | 12.5% |
| CR1 | 19 | 61.3% |
| CML in CP1 | 2 | 6.5% |
| High-risk gene mutationsb | ||
| No/yes | 11/20 | 35.5%/64.5% |
| High-risk cytogeneticsa, c | ||
| No/yes | 27/2 | 87.1%/6.5% |
| Conditioning regimen | ||
| Bu/Cy | 25 | 80.6% |
| Bu/flu | 4 | 12.9% |
| Cy/TBI | 2 | 6.5% |
| Time from diagnosis to transplantation (days) | ||
| Median (range) | 173 (84–2737) | |
| Age of donor (years) | ||
| Median (range) | 28 (17–55) | |
| < 40/ ≥ 40 | 23/8 | 74.2% |
| HLA matched loci | 25.8% | |
| 5/10 | 26 | 83.9% |
| 6/10 | 3 | 9.4% |
| 7/10 | 1 | 3.2% |
| 8/10 | 1 | 3.2% |
| Donor-recipient ABO match | ||
| Match | 13 | 40.6% |
| Major mismatch | 8 | 25.0% |
| Minor mismatch | 9 | 29.0% |
| Bidirectional mismatch | 1 | 3.2% |
| Donor-recipient gender match | ||
| Female to male | 7 | 22.6% |
| Female to female | 4 | 12.9% |
| Male to female | 9 | 29.0% |
| Male to male | 11 | 35.5% |
| Graft ( × 108/kg) | ||
| MNCs, median (range) | 9.7 (5.2–22.9) | |
| CD34+, median (range) | 4.2 (1.9–7.6) | |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; CP, chronic phase; CR, complete remission; CT, chemotherapy; LBL, lymphoblastic leukemia/lymphoma; MNCs, mononuclear cells; NHL, non-Hodgkin lymphoma; PCL, plasma cell leukemia; WBC, white blood cell
aInformation is not available in some cases
bHigh-risk gene mutations indicate TET2, DNMT3a, TP53, FLT3-ITD, and BCR-ABL T315I mutations
cHigh-risk cytogenetics was defined as: (i) ALL with hypodiploidy (< 44 chromosomes), t (4;11), (9;22), or t (1;19); (ii) AML with monosomy 5, monosomy 7, 11q23, inv.(3), t (3;3), or t (9;22); (iii) Disease with complex karyotype (≥ 3 chromosomal abnormalities) or − 17